John D. Shaughnessy

High Impact

Professor

UAMS

Last publication 2025 Last refreshed 2026-05-16

faculty

Internal Med, College of Medicine

jdshaughnessy@uams.edu

88 h-index 483 pubs 31,144 cited

Research Areas

Links

ORCID Google Scholar Lab Website Research Group UAMS TRI Profile

OverviewAI-generated summary

John D. Shaughnessy's research focuses on multiple myeloma, a type of cancer affecting plasma cells. His work investigates the genetic underpinnings of the disease, including cytogenetic alterations that contribute to its complexity and progression. He has also explored the role of specific genes and proteins, such as TRIP13 and CST6, in modulating tumor development and the associated bone disease in multiple myeloma.

Dr. Shaughnessy's publications also address novel therapeutic approaches for multiple myeloma. This includes research into bispecific antibodies and CAR-T cells designed to target specific markers on myeloma cells, such as BCMA and CD24, to control tumor growth. His research extends to understanding the metabolic pathways that support myeloma cell survival, including the role of AKT and FOXO activity. Furthermore, he has contributed to the development of prognostic scoring systems to better predict patient outcomes, such as the Myeloma Prognostic Score System (MPSS).

With a career marked by extensive publication and high citation counts (h-index: 88, total publications: 483, total citations: 31,036), Dr. Shaughnessy is recognized as a highly cited researcher. He collaborates with several colleagues at the University of Arkansas for Medical Sciences, including Fenghuang Zhan, Guido Tricot, Clyde Bailey, and Sharmilan Thanendrarajan, with whom he has co-authored numerous publications.

Metrics

h-index: 88
Publications: 483
Citations: 31,144

Selected Publications

Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)

DOI OpenAlex
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma (2026)

DOI OpenAlex
Gene Expression–Based prediction of 1q, 1p, 13q, and 17p chromosome ploidy in newly diagnosed and paired relapsed myeloma and across the plasma cell dyscrasia spectrum (2025)

DOI OpenAlex
The invisible divide: the impact of racial and geographic disparities on multiple myeloma outcomes - insights from a single-site study (2025)

DOI OpenAlex
Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging (2025)

DOI OpenAlex
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)

1 citation DOI OpenAlex
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025)

3 citations DOI OpenAlex
Abstract 860: BCMA CAR-T cells releasing mutant CST6 N137D proteins further improve therapeutic effects in multiple myeloma (2025)

DOI OpenAlex
Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experience (2025)

DOI OpenAlex
Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone Resorption (2025)

1 citation DOI OpenAlex
Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma (2025)

4 citations DOI OpenAlex
Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myeloma (2025)

5 citations DOI OpenAlex
Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets (2025)

4 citations DOI OpenAlex
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024)

5 citations DOI OpenAlex
Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages (2024)

1 citation DOI OpenAlex

View all publications on OpenAlex →

Grants & Funding

Developmental Funds Pilot of the Southwest Oncology Group-SWOG-01047 NIH/Nat. Cancer Institute Principal Investigator
Gene expression profiling vs MRD assessment in Myeloma NIH Co-Investigator
Studying the role of APRIL and BAFF signaling in Myelomagenesis and its Therapy ZymoGenetics, Inc Principal Investigator
Studying the role of APRIL and BAFF signaling in Myelomagenesis and its Therapy ZymoGenetics, Inc Principal Investigator
Preclinical Studies of the Mechanisms of Action of Velcade Millennium Pharmaceuticals, Inc. Principal Investigator
Molecular Diagnosis and Prognosis of Multiple Myeloma NIH/Nat. Cancer Institute Principal Investigator
U54 - Bioinformatics Core NIH/Nat. Cancer Institute - Pass Through: Baylor College of Medicine Principal Investigator
Preclinical Studies of the Mechanisms of Action of Velcade Millennium Pharmaceuticals, Inc. Principal Investigator